Urinary Bladder Diseases
1 competing product in clinical development for Urinary Bladder Diseases.
Pipeline by Phase
Phase 31
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placebo | Astellas Pharma | Phase 3 | Completed | 40 |